Ovid Therapeutics Inc (OVID) Actualités

Form 8-K - Current report

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date...